Myoguide ™  Injection Site Targeting System Earns CE Mark

Myoguide poised to become essential pain and spasticity treatment tool in hands of European physicians

We are extremely pleased to have obtained CE Mark approval for Myoguide. Clinicians throughout the European Union may now treat their patients suffering from acute and chronic pain, and spasticity with a highly portable electromyographic (EMG) precision device from Intronix Technologies Corp.. More accurate injection site targeting may enhance treatment of pain and spasticity, and improve the outcomes of treatment.